CD274 and neoplasm: Preclinical tests have revealed that PD-L1-targeted CAR-NK cells exhibit specific antitumor effects against several in vitro tumor cell lines, and exhibit robust in vivo antitumor effects against triple-negative breast cancer [116], bladder cancer [117], and lung cancer [118].